All In Biotech

Drug Trial Radar · NCT07028853

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Sep 28, 2025

Primary completion

Sep 12, 2028

Study completion Dec 8, 2034

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

Conditions

  • Metastatic Castration Sensitive Prostate Cancer (mCSPC)
  • Hormone Sensitive Prostate Cancer
  • Prostate Cancer
  • Cancer of the Prostate

Interventions

  • MevrometostatDrug

    Oral continuous

  • PlaceboDrug

    Oral continuous

  • EnzalutamideDrug

    Oral continuous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression Free Survival (rPFS)Time frame: Randomization up to approximately 4 years

Locations

319 sites in 26 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute (Crestwood)

    Huntsville, Alabama · Recruiting

  • Clearview Cancer Institute

    Huntsville, Alabama · Recruiting

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Chandler, Arizona · Recruiting

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Gilbert, Arizona · Recruiting

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Glendale, Arizona · Recruiting

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Goodyear, Arizona · Recruiting

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Mesa, Arizona · Recruiting

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Mesa, Arizona · Recruiting

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Phoenix, Arizona · Recruiting

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Scottsdale, Arizona · Recruiting

  • Highlands Oncology Group, PA

    Fayetteville, Arkansas · Recruiting

  • Highlands Oncology Group, PA

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group, PA

    Springdale, Arkansas · Recruiting

  • UCLA Hematology/Oncology - Alhambra

    Alhambra, California · Recruiting

  • UCLA Hematology/Oncology - Atascadero

    Atascadero, California · Recruiting

  • Cedars-Sinai Cancer Beverly Hills (drug treatment and dispensing location)

    Beverly Hills, California · Recruiting

  • Cedars-Sinai Cancer Beverly Hills

    Beverly Hills, California · Recruiting

  • UCLA Hematology/Oncology - Beverly Hills

    Beverly Hills, California · Recruiting

  • UCLA Hematology/Oncology - Burbank

    Burbank, California · Recruiting

  • UCLA Hematology/Oncology - Encino

    Encino, California · Recruiting

  • UCLA Hematology/Oncology - Irvine

    Irvine, California · Recruiting

  • UCLA Hematology/Oncology - Laguna Hills

    Laguna Hills, California · Recruiting

  • Cedars-Sinai Cancer at Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Ronald Reagan UCLA Medical Center - Drug Information Center

    Los Angeles, California · Recruiting

  • UCLA Department of Medicine - Hematology/Oncology

    Los Angeles, California · Recruiting

  • UCLA Hematology/Oncology

    Los Angeles, California · Recruiting

  • UCLA Hematology/Oncology - Marina del Rey

    Marina del Rey, California · Recruiting

  • UCLA Hematology/Oncology - Pasadena

    Pasadena, California · Recruiting

  • UCLA Hematology/Oncology - Porter Ranch

    Porter Ranch, California · Recruiting

  • UCLA Hematology/Oncology - San Luis Obispo

    San Luis Obispo, California · Recruiting

  • UCLA Hematology/Oncology - Santa Barbara

    Santa Barbara, California · Recruiting

  • UCLA Hematology/Oncology- Santa Monica

    Santa Monica, California · Recruiting

  • UCLA Hematology/Oncology - Torrance

    Torrance, California · Recruiting

  • UCLA Hematology/Oncology - Santa Clarita

    Valencia, California · Recruiting

  • UCLA Hematology/Oncology - Ventura

    Ventura, California · Recruiting

  • UCLA Hematology/Oncology - Westlake

    Westlake Village, California · Recruiting

  • AdventHealth Medical Group Urology of Denver

    Denver, Colorado · Recruiting

  • Advanced Urology Institute, LLC

    Largo, Florida · Recruiting

  • Tennessee Oncology, PLLC - Dalton

    Dalton, Georgia · Recruiting

  • Tennessee Oncology, PLLC - Ringgold

    Ringgold, Georgia · Recruiting

Showing 40 of 319 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.